Hosojima H, Miyauchi E, Okada H, Morimoto S
Department of Internal Medicine, Kanazawa Medical University, Ishikawa, Japan.
Nihon Naibunpi Gakkai Zasshi. 1990 Nov 20;66(11):1138-47. doi: 10.1507/endocrine1927.66.11_1138.
Hyperglycemia and impaired glucose tolerance are frequently observed in patients with hyperthyroidism. However, little is known about whether altered polyol metabolism in hyperthyroidism is present or not. To examine changes in polyol metabolism in hyperthyroidism, we investigated changes in erythrocyte sorbitol, glyceraldehyde reductase (GAR) and sorbitol dehydrogenase (SDH) activities during hyperthyroid and euthyroid states in patients with thyrotoxicosis. Mean levels of erythrocyte sorbitol and GAR were 32.0 +/- 1.6nM/g.Hb and 147.1 +/- 0.3mU/g.Hb, respectively. In thyrotoxic patients in a hyperthyroid state, these values were significantly higher than those in euthyroid controls. Mean level of erythrocyte SDH in thyrotoxic patients was weak but was significantly increased in comparison with that of euthyroid controls. However, mean levels of erythrocyte sorbitol and GAR were remarkably reduced to 23.6 +/- 1.4nM/g.Hb and 125.3 +/- 4.6mU/g.Hb in thyrotoxic patients in a euthyroid state after treatment with anti-thyroid drugs or by subtotal thyroidectomy. Mean level of SDH, on the other hand, was increased after the treatment. In addition, positive correlations were observed between the level of erythrocyte sorbitol or GAR, and the level of free thyroxine(FT4) or free triiodothyronine(FT3). A negative correlation was observed between the level of erythrocyte SDH and the level of FT4 or FT3. These results suggest that the level of erythrocyte sorbitol may be increased through direct acceleration of erythrocyte GAR activity by increased thyroid hormone levels in patients with thyrotoxicosis.
甲状腺功能亢进症患者常出现高血糖和糖耐量受损。然而,关于甲状腺功能亢进症中多元醇代谢是否改变尚知之甚少。为了研究甲状腺功能亢进症中多元醇代谢的变化,我们调查了甲状腺毒症患者甲状腺功能亢进和甲状腺功能正常状态下红细胞山梨醇、甘油醛还原酶(GAR)和山梨醇脱氢酶(SDH)活性的变化。红细胞山梨醇和GAR的平均水平分别为32.0±1.6nM/g.Hb和147.1±0.3mU/g.Hb。在甲状腺功能亢进状态的甲状腺毒症患者中,这些值显著高于甲状腺功能正常的对照组。甲状腺毒症患者红细胞SDH的平均水平较低,但与甲状腺功能正常的对照组相比显著升高。然而,在用抗甲状腺药物治疗或行甲状腺次全切除术后,处于甲状腺功能正常状态的甲状腺毒症患者红细胞山梨醇和GAR的平均水平显著降低至23.6±1.4nM/g.Hb和125.3±4.6mU/g.Hb。另一方面,治疗后SDH的平均水平升高。此外还观察到红细胞山梨醇或GAR水平与游离甲状腺素(FT4)或游离三碘甲状腺原氨酸(FT3)水平之间呈正相关。红细胞SDH水平与FT4或FT3水平之间呈负相关。这些结果表明,甲状腺毒症患者甲状腺激素水平升高可能通过直接加速红细胞GAR活性而使红细胞山梨醇水平升高。